GlassScriptPhysician profile
Nina A Bhatt
NPI 1669665881
$1,308.45
in general payments reported to CMS, 2019-2025
16 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $177 · 2021: $250 · 2022: $177 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $186.93 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $148.71 | 2022-2025 | Dupixent |
| Adma Biomanufacturing LLC | $147.40 | 2021-2025 | |
| Csl Behring | $137.86 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $113.81 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $109.08 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $93.74 | 2019-2020 | |
| Pfizer INC. | $63.95 | 2019-2021 | |
| Genzyme Corporation | $55.00 | 2021 | |
| Kaleo, INC. | $54.69 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $53.45 | 2019-2022 | |
| Glaxosmithkline, LLC. | $44.40 | 2019-2022 | |
| Genentech USA, INC. | $35.66 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $26.64 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.30 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nina Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.